ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,049.88
0.05%
US Tech 100
20,674.80
0.00%
Dow Jones
44,705.53
-0.17%
Brent Oil
73.735
0.18%
Bitcoin
96,671.57
0.73%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Geron Corp (GERN)

  7. Geron Corp (GERN) News

Geron Corp

Geron Corp (GERN)

NASDAQ
3.95
0.00
(0.00%)
Closed December 04 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

GERN News

Official News Only

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
GERN (0.00%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
November 14 2024
GERN (0.00%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
September 09 2024
GERN (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 09 2024
GERN (0.00%)

GERN Discussion

View Posts
stockrafter stockrafter 8 hours ago
A question to the board...

As owner of Halozyme shares, the Geron patent filing posted below, popped up looking at Halozyme patents.

Was wondering if anyone has heard of Geron working with Halozyme to develop SC injection of Rytelo?

Was going to listen to the Evercore presentation tomorrow to hear if they mention anything.

Thanks, SR

"Subcutaneous telomerase inhibitor compositions and methods for using same "

Ihttps://patents.google.com/patent/US20220168403A1/en

The filing has been rejected twice, so not sure if it future, but is does show interest in SC injection.
👍️0
Stumblebum Stumblebum 2 weeks ago
Sure is nice days that the price of geron goes up or stays the same we don’t have to hear the rantings of Jethro Bodines buddy
👍️ 1
learningcurve2020 learningcurve2020 2 weeks ago
RA Capital

>>The shares reported herein for the Reporting Persons represent (i) 32,285,755 shares of Common Stock held directly, and (ii) 31,033,798 shares of Common Stock that the Reporting Persons beneficially own based on the right to acquire, upon the exercise of Pre-Funded Warrants. The Pre-Funded Warrants contain a provision (the “Beneficial Ownership Blocker”) which precludes the exercise of the warrants to the extent that, following exercise, the Reporting Person, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The Reporting Person is currently prohibited from exercising the warrants to the extent that such exercise would result in beneficial ownership of more than 63,319,553 shares of Common Stock.
👍️0
Spike5 Spike5 3 weeks ago
Oh my it looks like we and I were correct . Too bad you let a spellcheck changing well to we dissuade getting rid of this crap
👍️0
Stumblebum Stumblebum 3 weeks ago
Hey it’s the “we I hope hope you read” is back …what have you and Jethro been up to
👍️0
Spike5 Spike5 3 weeks ago
Not even trump can save this useless pile of trash
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
Shrugs. LP's got the greatest job in the world.  
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
Like I said here many times I've been comparing Geron's "By the book" approach to LP's bizarre approach.  Geron is now the clear winner. 

>>"This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company.



>>In November 2024, completed synthetic royalty and debt financing transactions to strengthen our cash position and further solidify our balance sheet while providing strategic flexibility to invest in our future. We entered into a synthetic royalty agreement with Royalty Pharma providing $125 million of capital in exchange for tiered royalty payments. We also entered into a 5-year, senior term loan agreement with Pharmakon for up to $250 million, from which we have drawn a first tranche of $125 million, a portion of which was used to fully repay amounts owed under our existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has now been terminated, with the ability to borrow another $125 million prior to the end of 2025, subject to specified conditions.
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
Wow, nice!

Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of salesReceived $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
👍️0
Stumblebum Stumblebum 1 month ago
You need to reread your post 7806….quote and “yes this is a cancer cure”…..that’s ok dude I understand …..that’s what happens when you sit next to Jerhro Bodine
👍️0
Stumblebum Stumblebum 1 month ago
You said and I quote “ we I hope hope you read “…...and you talk about first grade education…..bhawhahahahahahahahaha
👍️0
Spike5 Spike5 1 month ago
We I hope hope you read the message I wrote making a complete fool of you over the cure . When you get that first grade education let me know moron .
👍️0
Stumblebum Stumblebum 1 month ago
There he is the basher man…..was expecting to hear from you since the stock is down today …..you must of been bored the last few days when Gern went up a bit ….bhawhahahaahahahaha
👍️0
Spike5 Spike5 1 month ago
This board is doing exactly what it should be doing shutting the hell up … there is no defending this garbage company
👍️0
learningcurve2020 learningcurve2020 1 month ago
It may be a quarter too early for that information.  I hope to hear that few patients are complaining about side effects or stopping treatment.  The revs will then follow.  

28% (n=33 out of 118) of patients taking RYTELO required ZERO red blood cell transfusions for 24 consecutive weeks or more vs 3% (n=2 out of 60) of patients taking placebo
👍️0
big bambino big bambino 1 month ago
Agreed, should be interesting heading to there, best to us all
👍️0
Stumblebum Stumblebum 1 month ago
Regarding earnings in two weeks…..I want to see increased revenues for rytelo …..that’s key and also and updates on European approval
👍️0
big bambino big bambino 1 month ago
picked up another 1k@4.03. Might use as swing or hold onto longer. Depending on what the earnings report has to say about their future plane's
👍️0
Spike5 Spike5 1 month ago
Oh wow ! This is done it will be in the twos by mid November. People on this board think they proved me wrong because I jokingly use the word cure . Anyone with a first grade education knows there is no cure for any cancer . What you can’t prove me wrong on is this is a poorly run company with a drug that very few people have a need for .
👍️0
learningcurve2020 learningcurve2020 1 month ago
Grrrrron back in the 3's.  Come on already! 
👍️0
big bambino big bambino 2 months ago
I haven't heard anything yet, 🤔
👍️0
Stumblebum Stumblebum 2 months ago
Well no news yes….but earnings first week of November…..what about European imetelstat approval?
👍️0
big bambino big bambino 2 months ago
Sorry 3k @ 4.04, for transparency
👍️0
big bambino big bambino 2 months ago
Picked up 3k. Massive swing with no news what so ever.
👍️0
Stumblebum Stumblebum 2 months ago
That’s all nice but currently under $4 🤮🫣
🤫 1
learningcurve2020 learningcurve2020 2 months ago
"Scotiabank Initiates Geron at Sector Outperform With $6 Price Target"


Geez, this stock never disappoints. Eye rolls.



>>Geron (GERN) has an average buy rating and a price target range of $5.50 to $10, according to analysts polled by Capital IQ.
👍️0
seward seward 2 months ago
Bought small shares to flip.
👍️0
Stumblebum Stumblebum 2 months ago
I did prove you wrong no where in Geron website nor info. On imetelstat does the word cure used….nice try though…..stick with bashing
👍️0
Spike5 Spike5 2 months ago
Funny I do not need to prove you wrong , you need to prove me wrong . Oh here is your apology, sorry YOU LOSE! Haha
👍️0
Stumblebum Stumblebum 2 months ago
Oh and spike so there is no hard feeling ….no need to apologize
👍️0
Stumblebum Stumblebum 2 months ago
Hey it’s the market maker basher again…..tell me dude where does geron say that imetelstat CURES cancer…..maybe it says can stop the spread and division of cells….NO where does it uses the word CURE….but nice try anyway….
👍️0
Spike5 Spike5 2 months ago
WOW!!!! Longs should be absolutely irate over this stock …. How many effing years has this been and it cannot even get to 5 after fda approval .
👍️0
Spike5 Spike5 2 months ago
1/4 step forward and then 3 steps back . Total joke yes this is a cancer cure haha
👍️0
Spike5 Spike5 2 months ago
It’s over shorts will win like I have said all along … this is done I told people what a shit company this is
👍️0
Spike5 Spike5 2 months ago
If it goes under 4 it will do a RS within one year .
👍️0
learningcurve2020 learningcurve2020 2 months ago
Everyone's just waiting to see if there's any market penetration. Retail will be the last to know either way.
👍️0
Spike5 Spike5 2 months ago
This company can’t even cure its own cancer . Management
👍️0
big bambino big bambino 2 months ago
Seeing all this price swing back and forth (with no announcement) gives credence to manipulation. JUST MY HONEST OPINION!
👍️0
attilathehunt attilathehunt 2 months ago
Probably funds reshuffling for quarter end.
👍️0
big bambino big bambino 2 months ago
1 1/2 hours into overtime, 550,000 shares traded, ummmmmmmmmm
👍️0
Stumblebum Stumblebum 2 months ago
The dude had the day off Gern up 8%….
👍️ 1 😀 2 🤣 1
Stumblebum Stumblebum 2 months ago
He probably works at a market maker and gets paid to bash the stock cause his employer is shorting the shares…..that’s his job
👍️ 3
luckygm luckygm 2 months ago
Instead of complaining all the time, why don't you buy down here at sell when it goes up 10%. You could have made a fortune doing that over the past 6 months.
👍️0
Spike5 Spike5 2 months ago
Wow 10 % loss is a disaster . Now you know why I have not one good thing to say about this company . Management is making a killing and killing longs in the process .
👍️0
Spike5 Spike5 2 months ago
This very well may be the dam breaking today … the shorts are going to keep driving this down to nothing . It’s a shame because this could have been a good thing but it is so poorly run and they have no news on anything coming out anytime soon . This amazes me that it cannot even get above five and now it’s going under 4 . Maybe even today
👍️0
Stumblebum Stumblebum 2 months ago
These new hires are probably salespeople to push the imetelstat drug
👍️0
Stumblebum Stumblebum 2 months ago
IMO a BO will occur next spring or summer once there is a definitive record of sales and forecast profitability…..$10 a share would be nice at the minimum
👍️0
attilathehunt attilathehunt 2 months ago
Those new stock options announced after the close for newly hired 'ee's are an incentive to stay on in the very likely event of a BO...

They will need them to stay on to ensure an orderly transition.

BO before end of year is my prediction.
👍️ 2
big bambino big bambino 2 months ago
closer & closer
👍️0
big bambino big bambino 2 months ago
getting closer 7 closer to that sub $4 mark
👍️0

Your Recent History

NASDAQ
GERN
Geron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved